The 2026/27 Community Pharmacy Contractual Framework: what it means for community pharmacy

After months of anticipation, the Community Pharmacy Contractual Framework (CPCF) for 2026/27 has now been agreed. While negotiations around pharmacy funding rarely exist in isolation, this year's settlement has attracted particular attention due to the wider pressures facing the sector, the continued rollout of Pharmacy First, and the forthcoming expansion of independent prescribing. 

For pharmacy owners and staff, the contract provides both immediate changes and longer-term signals about the direction of travel for community pharmacy. It offers additional investment and new opportunities, whilst also raising important questions about how pharmacies will continue to balance growing clinical expectations with ongoing financial and workforce pressures. 

 

The funding settlement 

The agreement provides a 10.3% increase in funding for community pharmacy in 2026/27, taking the annual CPCF funding envelope to £3.39 billion. 

Alongside the core settlement, several financial measures have been introduced or maintained. The retained medicines margin remains at £900 million, while the Single Activity Fee (SAF) will increase to £1.53 per item. The Pharmacy Quality Scheme (PQS) will also continue, providing pharmacies with an additional route to earn funding through quality improvement and service delivery. 

The contract builds on commitments made during last year's negotiations, including the write-off of historic margin over-delivery and ongoing work to review medicines margin distribution and branded generics reimbursement. 

For many pharmacy businesses, these changes will provide some welcome stability. However, it is important to note that funding remains one of the most debated issues in the sector. Many contractors continue to argue that rising costs, including inflation, National Insurance changes and workforce expenses, have significantly increased operating pressures in recent years. 

 

Independent prescribing moves closer 

Perhaps the most significant long-term development within the contract is the introduction of a national NHS independent prescribing offer from autumn 2026. 

The new service will sit within Pharmacy First and the Pharmacy Contraception Service, with up to five new prescribing-only pathways expected to be added over time. To support implementation, participating pharmacies will receive a one-off £500 set-up payment alongside a monthly infrastructure payment of £525. 

The move comes at a pivotal moment for the profession. This summer will see the first cohort of pharmacists qualify as independent prescribers upon registration, fundamentally changing the capabilities of the future workforce. 

The transition will not be without challenges. Earlier this month, the General Pharmaceutical Council (GPhC) published guidance for newly qualified prescribing pharmacists, emphasising that although pharmacists will register as prescribers from day one, they must continue to prescribe only within their competence and scope of practice. The guidance also highlighted the importance of supervision, professional judgement, and ongoing development, reflecting wider conversations across the sector about how newly qualified prescribers will be supported in practice. 

For pharmacy owners, the challenge now becomes preparing themselves for this change. Workforce planning, governance arrangements, consultation capacity, and training pathways will all need careful consideration as prescribing becomes more deeply embedded within everyday practice. 

 

Pharmacy First and service development 

The contract also continues the government's broader ambition to expand the clinical role of community pharmacy, including a commitment to review the delivery of Pharmacy First and other nationally commissioned services. 

Alongside this, the government has committed to considering actions arising from recommendations on medicines shortages and supply chain resilience. This reflects ongoing concern across the sector, with many pharmacies continuing to report daily challenges obtaining medicines and managing patient expectations during shortages. 

The agreement also includes a review of pharmacy payment timetables, including options for earlier dispensing payments. While this may sound administrative, many contractors have argued that cashflow remains a significant operational challenge, making this an area of considerable interest. 

 

A contract aligned with a changing NHS 

Looking beyond the individual measures, the contract reinforces a broader strategic shift already underway across the NHS. 

Community pharmacy is increasingly being positioned as a clinical front door to primary care, rather than solely a dispensing service. The expansion of Pharmacy First, the introduction of prescribing pathways and continued investment in preventative services all point in the same direction. This aligns with wider NHS priorities around neighbourhood health, prevention and delivering more care closer to home. 

For pharmacy teams, this presents both opportunities and challenges. Clinical services offer new routes for growth and professional development, but they also require sufficient workforce capacity, training, and infrastructure to deliver them safely and sustainably. 

 

How has the sector responded? 

Reaction to the settlement has been mixed. Community Pharmacy England voted to accept the agreement but has been clear that it does not view the deal as a complete solution to the sector's financial challenges. Writing after the vote, Chief Executive Janet Morrison said committee members recognised the severe pressures facing pharmacy businesses but concluded that the settlement represented the best available outcome from negotiations and secured several important commitments for future reform, including work towards a sustainable funding and operating model, reviews of medicines margin arrangements, and further discussions on service development and medicines supply. 

That position reflects a broader mood across the sector. While many pharmacy leaders have welcomed the additional investment and the recognition of community pharmacy's growing clinical role, others have pointed out that significant challenges remain. Rising operating costs, workforce pressures and ongoing concerns around long-term sustainability mean that some contractors view the settlement as a major step forward, but not yet a complete answer to the financial difficulties facing the sector. 

Independent prescribing has generated a similarly mixed response. Many see it as one of the profession's biggest opportunities in decades, offering a route to expand clinical services and demonstrate pharmacy's value within primary care. Others have raised questions around implementation, workforce readiness, governance requirements and whether sufficient support will be available for pharmacies introducing prescribing services. 

In short, there is broad agreement that the contract moves community pharmacy forward. The debate centres on whether it moves far enough, and whether the pace of change is matched by the resources needed to deliver it. 

 

What happens next? 

While much of the immediate attention has focused on the funding settlement, the longer-term significance of this contract may lie elsewhere. The introduction of a national independent prescribing offer, continued expansion of clinical services, and commitments to review key aspects of the funding model all point towards a profession that is continuing to evolve beyond its traditional dispensing role. 

For pharmacy owners and managers, the challenge will be balancing today's operational realities with tomorrow's opportunities. Decisions around workforce development, service expansion and prescribing capability are likely to become increasingly important as the NHS looks to make greater use of community pharmacy's clinical expertise. 

Whether the contract proves to be a turning point for the sector remains to be seen. What is clear, however, is that the next twelve months will play a significant role in shaping how community pharmacy delivers care, generates income and positions itself within the wider health system.